Please assess the completion status of the following clinical trial:

Trial Title: PET/CT Guided Fulvestrant Therapy for Patients With Recurrent or Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* post-menopausal (≥ 60 years old, or age ≥ 45 years with amenorrhea for \> 12 months or follicle stimulating hormone and estrogen levels within post-menopausal range, or prior bilateral oophorectomy)~* hormone receptor positive (ER and/or PgR) disease as determined locally~* WHO performance status 0-2~* life expectancy of ≥ 3 months~* the presence of at least one measurable or evaluable (non-measurable) lesion~* informed consent prior to any study procedures~Exclusion Criteria:~* life threatening metastatic visceral disease~* brain or leptomeningeal metastases~* prior exposure to fulvestrant~* history of bleeding diathesis or need for long term anti-coagulation

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PET/CT Guided FES Therapy (Type: EXPERIMENTAL): All subjects will be seen at baseline and then monthly until month 6 of fulvestrant therapy unless clinical or radiological progression or unacceptable toxicity earlier than month 6.

Based on this trial design, predict the completion outcome and termination type (if applicable).